Hadly Clark is a director at Milken Institute’s FasterCures. She is an experienced health care professional focused on the intersection of health and technology. Clark leads digital health and oncology-focused initiatives exploring innovative diagnostic technologies and advancements in anticancer treatments.
Technological innovation in the health landscape is occurring rapidly, and much of it would not be possible without patient data. Health data sets can be leveraged to build new tools that can help diagnose disease, remotely monitor and track patients, and make groundbreaking discoveries that lead to new treatments and cures. Technology companies, which have already disrupted countless industries, have the most advanced capabilities to organize data, create consumer products based on data-driven insights, and make information universally accessible in ways that are certainly applicable to the health space.
However, because they have not traditionally played a central role in the healthcare landscape, their participation carries substantial implications for how patient data are collected and used. This environment of uncertainty impacts patients’ levels of trust and, as a result, their levels of engagement in biomedical research.
This report summarizes our interview series on data-driven patient participation in research, and our private roundtable focused on building trust to achieve a shared vision for patient data. It describes key themes that have emerged from these efforts and briefly mentions upcoming work that will build on this foundation.
The rapid advancement of the health technology landscape relies heavily on patient data. Patient data from medical records and digital health apps can be leveraged to build new tools that can help diagnose disease, remotely monitor and...
New blood-based technologies, known as multi-cancer early detection (MCED) tests, are entering the market and can identify multiple cancers early and simultaneously. These tests detect signals found in DNA that cancer cells shed into the...
The fuel for biomedical innovation is data. Data-driven patient participation — or patient contribution of their biospecimens, self-reported or wearable data, health record data, and other information — has emerged as a tool that may help...
The United States biomedical research and innovation enterprise has long been a source of global leadership, scientific breakthroughs, and lifesaving treatments. Decades of investments in research and development have positioned the US as...
The United States biomedical research and innovation enterprise has long been a source of global leadership, scientific breakthroughs, and lifesaving treatments.
Three in four adults over age 50 want to age at home. However, increasing home care needs, direct care workforce shortages, and fewer family caregivers create gaps in support. At the same time, the care landscape is shifting. Telehealth...
Overview On October 30, 2023, President Joe Biden signed an executive order that establishes new federal standards and regulations for the safe and ethical use of artificial intelligence (AI). Covering a wide set of sectors potentially...
The 26th annual Milken Institute Global Conference convened the best minds in the world to tackle its most urgent challenges and realize its most exciting opportunities. Throughout the four-day event, our health teams curated nearly three...
If the objective of biomedical research is to spur innovation to create healthier communities, extend life, and more effectively treat or cure disease, then persistent inequities run counter to that goal and create unnecessary barriers to...
As patients, we often evaluate our interactions within the "system" of biomedical innovation with a simple question: "Did it work for me?" This evaluation considers many issues, including whether the best treatments are accessible and...